APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD19-targeted CAR-T Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CD19-targeted CAR-T Cell Therapy Market Analysis and Forecast 2026-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchCD19-targeted CAR-T Cell Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal CD19-targeted CAR-T Cell Therapy Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal CD19-targeted CAR-T Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD19-targeted CAR-T Cell Therapy Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal CD19-targeted CAR-T Cell Therapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global CD19-targeted CAR-T Cell Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CD19-targeted CAR-T Cell Therapy include Bristol-Myers Squibb (Breyanzi), Gilead (Yescarta&Tecartus), Novartis (Kymriah), FOSUNKite (Yescarta), Juventas and Shanghai Yaoming Juno (Carteyva), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CD19-targeted CAR-T Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CD19-targeted CAR-T Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for CD19-targeted CAR-T Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CD19-targeted CAR-T Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CD19-targeted CAR-T Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CD19-targeted CAR-T Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

CD19-targeted CAR-T Cell Therapy Segment by Company

Bristol-Myers Squibb (Breyanzi)

Gilead (Yescarta&Tecartus)

Novartis (Kymriah)

FOSUNKite (Yescarta)

Juventas

Shanghai Yaoming Juno (Carteyva)

CD19-targeted CAR-T Cell Therapy Segment by Type

Yescarta

Tecartus

Kymriah

Others

CD19-targeted CAR-T Cell Therapy Segment by Application

Lymphoma

Lymphocytic Leukemia

CD19-targeted CAR-T Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD19-targeted CAR-T Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD19-targeted CAR-T Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD19-targeted CAR-T Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CD19-targeted CAR-T Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CD19-targeted CAR-T Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CD19-targeted CAR-T Cell Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Yescarta Major Player Table 3. Tecartus Major Player Table 4. Kymriah Major Player Table 5. Others Major Player Table 6. Global CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Lymphoma Major Player Table 8. Lymphocytic Leukemia Major Player Table 9. CD19-targeted CAR-T Cell Therapy Industry Trends Table 10. CD19-targeted CAR-T Cell Therapy Industry Drivers Table 11. CD19-targeted CAR-T Cell Therapy Industry Opportunities and Challenges Table 12. CD19-targeted CAR-T Cell Therapy Industry Restraints Table 13. Global CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 15. Global CD19-targeted CAR-T Cell Therapy Market Share by Region (2021-2026) Table 16. Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2027-2032) & (US$ Million) Table 17. Global CD19-targeted CAR-T Cell Therapy Market Share by Region (2027-2032) Table 18. Global CD19-targeted CAR-T Cell Therapy Revenue by Players (US$ Million) & (2021-2026) Table 19. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Players (2021-2026) Table 20. Global CD19-targeted CAR-T Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global CD19-targeted CAR-T Cell Therapy Key Players Headquarters & Area Served Table 22. Global CD19-targeted CAR-T Cell Therapy Players, Product Type & Application Table 23. Global CD19-targeted CAR-T Cell Therapy Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global CD19-targeted CAR-T Cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global CD19-targeted CAR-T Cell Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 28. Global CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 29. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021-2026) Table 30. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Type (2027-2032) Table 31. Global CD19-targeted CAR-T Cell Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 33. Global CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 34. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021-2026) Table 35. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2027-2032) Table 36. Bristol-Myers Squibb (Breyanzi) Company Information Table 37. Bristol-Myers Squibb (Breyanzi) Business Overview Table 38. Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 40. Bristol-Myers Squibb (Breyanzi) Recent Development Table 41. Gilead (Yescarta&Tecartus) Company Information Table 42. Gilead (Yescarta&Tecartus) Business Overview Table 43. Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 45. Gilead (Yescarta&Tecartus) Recent Development Table 46. Novartis (Kymriah) Company Information Table 47. Novartis (Kymriah) Business Overview Table 48. Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 50. Novartis (Kymriah) Recent Development Table 51. FOSUNKite (Yescarta) Company Information Table 52. FOSUNKite (Yescarta) Business Overview Table 53. FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 55. FOSUNKite (Yescarta) Recent Development Table 56. Juventas Company Information Table 57. Juventas Business Overview Table 58. Juventas CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Juventas CD19-targeted CAR-T Cell Therapy Product Portfolio Table 60. Juventas Recent Development Table 61. Shanghai Yaoming Juno (Carteyva) Company Information Table 62. Shanghai Yaoming Juno (Carteyva) Business Overview Table 63. Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 65. Shanghai Yaoming Juno (Carteyva) Recent Development Table 66. North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 67. North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 68. North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 69. North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 70. North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 71. North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 72. North America CD19-targeted CAR-T Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 73. Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 74. Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 75. Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 76. Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 77. Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 79. Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 80. China CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 81. China CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 82. China CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 83. China CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 84. Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 85. Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 86. Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 87. Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 88. Asia CD19-targeted CAR-T Cell Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Asia CD19-targeted CAR-T Cell Therapy Revenue by Region (US$ Million) & (2021-2026) Table 90. Asia CD19-targeted CAR-T Cell Therapy Revenue by Region (US$ Million) & (2027-2032) Table 91. SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 92. SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 93. SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 94. SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 95. SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 97. SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. CD19-targeted CAR-T Cell Therapy Image Figure 2. Global CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD19-targeted CAR-T Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Yescarta Image Figure 5. Tecartus Image Figure 6. Kymriah Image Figure 7. Others Image Figure 8. Global CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global CD19-targeted CAR-T Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 10. Lymphoma Image Figure 11. Lymphocytic Leukemia Image Figure 12. Global CD19-targeted CAR-T Cell Therapy Market Size (US$ Million) & (2021-2032) Figure 13. Global CD19-targeted CAR-T Cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global CD19-targeted CAR-T Cell Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global CD19-targeted CAR-T Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global CD19-targeted CAR-T Cell Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021-2032) Figure 20. Global CD19-targeted CAR-T Cell Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021-2032) Figure 23. North America CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 25. North America CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 26. North America CD19-targeted CAR-T Cell Therapy Revenue Share by Country (2021-2032) Figure 27. United States CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 32. Europe CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 33. Europe CD19-targeted CAR-T Cell Therapy Revenue Share by Country (2021-2032) Figure 34. Germany CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 44. China CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 45. Asia CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 47. Asia CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 48. Asia CD19-targeted CAR-T Cell Therapy Revenue Share by Region (2021-2032) Figure 49. Japan CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 57. SAMEA CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 58. SAMEA CD19-targeted CAR-T Cell Therapy Revenue Share by Country (2021-2032) Figure 59. Brazil CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt CD19-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Yescarta
  • Tecartus
  • Kymriah
  • Others
Applications
  • Lymphoma
  • Lymphocytic Leukemia
Companies covered
  • Bristol-Myers Squibb (Breyanzi)
  • Gilead (Yescarta&Tecartus)
  • Novartis (Kymriah)
  • FOSUNKite (Yescarta)
  • Juventas
  • Shanghai Yaoming Juno (Carteyva)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CD19-targeted CAR-T Cell Therapy Market by Type
  3. 1.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Yescarta
  5. 1.2.3 Tecartus
  6. 1.2.4 Kymriah
  7. 1.2.5 Others
  8. 1.3 CD19-targeted CAR-T Cell Therapy Market by Application
  9. 1.3.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Lymphoma
  11. 1.3.3 Lymphocytic Leukemia
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 CD19-targeted CAR-T Cell Therapy Market Dynamics
  1. 2.1 CD19-targeted CAR-T Cell Therapy Industry Trends
  2. 2.2 CD19-targeted CAR-T Cell Therapy Industry Drivers
  3. 2.3 CD19-targeted CAR-T Cell Therapy Industry Opportunities and Challenges
  4. 2.4 CD19-targeted CAR-T Cell Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CD19-targeted CAR-T Cell Therapy Market Perspective (2021-2032)
  2. 3.2 Global CD19-targeted CAR-T Cell Therapy Growth Trends by Region
  3. 3.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Players
  2. 4.1.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CD19-targeted CAR-T Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CD19-targeted CAR-T Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CD19-targeted CAR-T Cell Therapy Key Players Headquarters & Area Served
  7. 4.4 Global CD19-targeted CAR-T Cell Therapy Players, Product Type & Application
  8. 4.5 Global CD19-targeted CAR-T Cell Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CD19-targeted CAR-T Cell Therapy Market CR5 and HHI
  11. 4.6.3 2025 CD19-targeted CAR-T Cell Therapy Tier 1, Tier 2, and Tier 3
5 CD19-targeted CAR-T Cell Therapy Market Size by Type
  1. 5.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 5.3 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021-2032)
6 CD19-targeted CAR-T Cell Therapy Market Size by Application
  1. 6.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  3. 6.3 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb (Breyanzi)
  2. 7.1.1 Bristol-Myers Squibb (Breyanzi) Company Information
  3. 7.1.2 Bristol-Myers Squibb (Breyanzi) Business Overview
  4. 7.1.3 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb (Breyanzi) Recent Developments
  7. 7.2 Gilead (Yescarta&Tecartus)
  8. 7.2.1 Gilead (Yescarta&Tecartus) Company Information
  9. 7.2.2 Gilead (Yescarta&Tecartus) Business Overview
  10. 7.2.3 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product Portfolio
  12. 7.2.5 Gilead (Yescarta&Tecartus) Recent Developments
  13. 7.3 Novartis (Kymriah)
  14. 7.3.1 Novartis (Kymriah) Company Information
  15. 7.3.2 Novartis (Kymriah) Business Overview
  16. 7.3.3 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product Portfolio
  18. 7.3.5 Novartis (Kymriah) Recent Developments
  19. 7.4 FOSUNKite (Yescarta)
  20. 7.4.1 FOSUNKite (Yescarta) Company Information
  21. 7.4.2 FOSUNKite (Yescarta) Business Overview
  22. 7.4.3 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product Portfolio
  24. 7.4.5 FOSUNKite (Yescarta) Recent Developments
  25. 7.5 Juventas
  26. 7.5.1 Juventas Company Information
  27. 7.5.2 Juventas Business Overview
  28. 7.5.3 Juventas CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Juventas CD19-targeted CAR-T Cell Therapy Product Portfolio
  30. 7.5.5 Juventas Recent Developments
  31. 7.6 Shanghai Yaoming Juno (Carteyva)
  32. 7.6.1 Shanghai Yaoming Juno (Carteyva) Company Information
  33. 7.6.2 Shanghai Yaoming Juno (Carteyva) Business Overview
  34. 7.6.3 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product Portfolio
  36. 7.6.5 Shanghai Yaoming Juno (Carteyva) Recent Developments
8 North America
  1. 8.1 North America CD19-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 8.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 8.3 North America CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 8.5 North America CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America CD19-targeted CAR-T Cell Therapy Revenue by Country
  11. 8.6.1 North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe CD19-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 9.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country
  11. 9.6.1 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China CD19-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 10.2 China CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 10.3 China CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 10.5 China CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CD19-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 11.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country
  11. 11.6.1 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 12.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country
  11. 12.6.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst